$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx

$egrx Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000082787121000011 Filed on March 05, 2021

Income Statement

Concept	2020 Q4	2019 Q4	2019
Revenue	$49.92M	$48.26M	$195.9M
YoY Change	3.44%	-13.91%	-8.17%
Cost Of Revenue	$12.54M	$11.59M	$47.89M
YoY Change	8.2%	-37.55%	13.02%
Gross Profit	$37.38M	$36.67M	$135.0M
YoY Change	1.94%	-2.21%	-10.83%
Gross Profit Margin	74.88%	75.98%	68.91%
Selling, General & Admin	$18.19M	$22.46M	$76.37M
YoY Change	-19.01%	45.09%	26.21%
% of Gross Profit	48.66%	61.25%	56.57%
Research & Development	$9.400M	$11.31M	$36.81M
YoY Change	-16.89%	93.0%	-17.13%
% of Gross Profit	25.15%	30.85%	27.27%
Depreciation & Amortization	$880.0K	$1.280M	$972.0K
YoY Change	-31.25%	52.38%	-15.84%
% of Gross Profit	2.35%	3.49%	0.72%
Operating Expenses	$27.58M	$33.77M	$113.2M
YoY Change	-18.33%	58.32%	-35.95%
Operating Profit	$9.800M	$2.897M	$21.82M
YoY Change	238.28%	-81.58%	-40.42%
Interest Expense	-$390.0K	-$240.0K	$2.686M
YoY Change	62.5%	-52.0%	-1.83%
% of Operating Profit	-3.98%	-8.28%	12.31%
Other Income/Expense, Net	$1.990M	$700.0K	$183.0K
YoY Change	184.29%		-107.1%
Pretax Income	$11.39M	$3.360M	$22.00M
YoY Change	238.99%	-77.94%	-35.37%
Income Tax	$3.330M	$2.350M	$7.685M
% Of Pretax Income	29.24%	69.94%	34.93%
Net Earnings	$8.060M	$1.010M	$14.31M
YoY Change	698.02%	-91.98%	-55.14%
Net Earnings / Revenue	16.15%	2.09%	7.31%
Basic Earnings Per Share		$0.08	$1.04
Diluted Earnings Per Share	$604.7K	$0.08	$1.01
COMMON SHARES
Basic Shares Outstanding	13.03M shares	13.67M shares	13.75M shares
Diluted Shares Outstanding			14.14M shares

Balance Sheet

Concept	2020 Q4	2019 Q4	2019
SHORT-TERM ASSETS
Cash & Short-Term Investments	$103.2M	$109.8M	$109.8M
YoY Change	-6.05%	39.34%	39.34%
Cash & Equivalents	$103.2M	$109.8M	$109.8M
Short-Term Investments	$0.00
Other Short-Term Assets	$1.605M	$1.445M	$15.10M
YoY Change	11.07%	978.36%	46.6%
Inventory	$8.075M	$6.566M	$6.600M
Prepaid Expenses
Receivables	$51.12M	$48.00M	$48.00M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$166.1M	$179.4M	$179.4M
YoY Change	-7.46%	9.52%	9.52%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.077M	$2.202M	$5.900M
YoY Change	-5.68%	-8.14%	145.83%
Goodwill	$39.74M	$39.74M
YoY Change	0.0%	0.0%
Intangibles	$12.92M	$15.58M
YoY Change	-17.11%	-13.92%
Long-Term Investments
YoY Change
Other Assets	$17.21M	$3.908M	$13.90M
YoY Change	340.33%	463.11%	-4.14%
Total Long-Term Assets	$87.13M	$75.11M	$75.20M
YoY Change	16.0%	0.46%	0.53%
TOTAL ASSETS
Total Short-Term Assets	$166.1M	$179.4M	$179.4M
Total Long-Term Assets	$87.13M	$75.11M	$75.20M
Total Assets	$253.2M	$254.6M	$254.6M
YoY Change	-0.54%	6.69%	6.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.268M	$5.462M	$5.500M
YoY Change	14.76%	-44.92%	-44.44%
Accrued Expenses	$23.82M	$28.36M	$28.40M
YoY Change	-16.02%	20.59%	20.85%
Deferred Revenue	$4.966M	$8.364M
YoY Change	-40.63%	42.51%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$8.000M	$5.000M	$5.000M
YoY Change	60.0%	-20.0%	-20.63%
Total Short-Term Liabilities	$38.09M	$38.82M	$38.80M
YoY Change	-1.9%	-2.17%	-2.27%
LONG-TERM LIABILITIES
Long-Term Debt	$25.14M	$33.56M	$33.60M
YoY Change	-25.1%	-12.05%	-12.04%
Other Long-Term Liabilities	$3.959M	$3.000M	$3.000M
YoY Change	31.97%
Total Long-Term Liabilities	$29.09M	$36.56M	$36.60M
YoY Change	-20.41%	-4.19%	-4.19%
TOTAL LIABILITIES
Total Short-Term Liabilities	$38.09M	$38.82M	$38.80M
Total Long-Term Liabilities	$29.09M	$36.56M	$36.60M
Total Liabilities	$67.18M	$75.38M	$75.40M
YoY Change	-10.88%	-3.16%	-3.08%
SHAREHOLDERS EQUITY
Retained Earnings	$84.49M	$72.50M
YoY Change	16.54%	24.6%
Common Stock	$17.00K	$17.00K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$203.9M	$171.9M
YoY Change	18.64%	11.67%
Treasury Stock Shares	3.682M shares	2.908M shares
Shareholders Equity	$186.0M	$179.2M	$179.2M
YoY Change
Total Liabilities & Shareholders Equity	$253.2M	$254.6M	$254.6M
YoY Change	-0.54%	6.69%	6.71%

Cashflow Statement

Concept	2020 Q4	2019 Q4	2019
OPERATING ACTIVITIES
Net Income	$8.060M	$1.010M	$14.31M
YoY Change	698.02%	-91.98%	-55.14%
Depreciation, Depletion And Amortization	$880.0K	$1.280M	$972.0K
YoY Change	-31.25%	52.38%	-15.84%
Cash From Operating Activities	$19.76M	-$3.200M	$55.99M
YoY Change	-717.5%	-108.4%	6.88%
INVESTING ACTIVITIES
Capital Expenditures	-$170.0K	-$130.0K	$777.0K
YoY Change	30.77%	62.5%	484.21%
Acquisitions
YoY Change
Other Investing Activities	$0.00
YoY Change
Cash From Investing Activities	-$170.0K	-$130.0K	-$777.0K
YoY Change	30.77%	62.5%	484.21%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$17.96M
YoY Change			-75.43%
Debt Paid & Issued, Net			$6.000M
YoY Change			60.0%
Cash From Financing Activities	-6.120M	-4.110M	-$24.23M
YoY Change	48.91%	-91.85%	-72.51%
NET CHANGE
Cash From Operating Activities	19.76M	-3.200M	$55.99M
Cash From Investing Activities	-170.0K	-130.0K	-$777.0K
Cash From Financing Activities	-6.120M	-4.110M	-$24.23M
Net Change In Cash	13.47M	-7.440M	$30.98M
YoY Change	-281.05%	-40.19%	-186.39%
FREE CASH FLOW
Cash From Operating Activities	$19.76M	-$3.200M	$55.99M
Capital Expenditures	-$170.0K	-$130.0K	$777.0K
Free Cash Flow	$19.93M	-$3.070M	$55.21M
YoY Change	-749.19%	-108.04%	5.66%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0000827871
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	us-gaap:ProductMember
CY2018	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	us-gaap:ProductMember
CY2019	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	us-gaap:ProductMember
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesNoncurrent
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:AccruedLiabilitiesCurrent
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity Registrant Name EntityRegistrantName	Eagle Pharmaceuticals, Inc.
CY2020	dei	Entity File Number EntityFileNumber	001-36306
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-8179278
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	50 Tice Boulevard
CY2020	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 315
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Woodcliff Lake
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07677
CY2020	dei	City Area Code CityAreaCode	201
CY2020	dei	Local Phone Number LocalPhoneNumber	326-5300
CY2020	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value per share
CY2020	dei	Trading Symbol TradingSymbol	EGRX
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	514326120	USD
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13217284	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	103155000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	109775000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	51117000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	48004000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	8075000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	6566000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3718000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15104000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	166065000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	179449000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2077000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2202000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	12917000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	15583000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	39743000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	39743000	USD
CY2020Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	15180000	USD
CY2019Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	13669000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	17208000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3908000	USD
CY2020Q4	us-gaap	Assets Assets	253190000	USD
CY2019Q4	us-gaap	Assets Assets	254554000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6268000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5462000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23817000	USD
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	28361000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	8000000	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	5000000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	38085000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	38823000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3959000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3000000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	25135000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	33557000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	67179000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	75380000	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16739203	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16537846	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	17000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	17000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	305403000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	278518000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	84489000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	72500000	USD
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	3682176	shares
CY2019Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	2907687	shares
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	203898000	USD
CY2019Q4	us-gaap	Treasury Stock Value TreasuryStockValue	171861000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	186011000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	179174000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	253190000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	254554000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	187802000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	195892000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	213312000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	33647000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	47891000	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	42374000	USD
CY2020	us-gaap	Royalty Expense RoyaltyExpense	11818000	USD
CY2019	us-gaap	Royalty Expense RoyaltyExpense	13006000	USD
CY2018	us-gaap	Royalty Expense RoyaltyExpense	19542000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30785000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	36810000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44419000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	78598000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	76370000	USD
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	60509000	USD
CY2020	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2019	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2018	us-gaap	Restructuring Charges RestructuringCharges	7911000	USD
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2019	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2018	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2704000	USD
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2018	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-763000	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	154848000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	36616000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	174077000	USD
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	176696000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	32954000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	21815000	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	562000	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	2169000	USD
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	158000	USD
CY2020	us-gaap	Interest Expense InterestExpense	2577000	USD
CY2019	us-gaap	Interest Expense InterestExpense	2686000	USD
CY2018	us-gaap	Interest Expense InterestExpense	2736000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-8262000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	700000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10277000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	183000	USD
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2578000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	22677000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	21998000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	34038000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10688000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7685000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2135000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	11989000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	14313000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	31903000	USD
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.89
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.04
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.16
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.87
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.01
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.09
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13481525	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13754516	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14138733	shares
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14768625	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13771393	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15278651	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	179144000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	19082000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8615000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	-4877000	USD
CY2018	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	73105000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	31903000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	160762000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	21998000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	260000	USD
CY2019	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	198000	USD
CY2019	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	17961000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	14313000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	179174000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24756000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3654000	USD
CY2020	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1525000	USD
CY2020	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	32037000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	11989000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	186011000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	11989000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	14313000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	31903000	USD
CY2020	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-1511000	USD
CY2019	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	152000	USD
CY2018	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-2468000	USD
CY2020	us-gaap	Depreciation Depreciation	872000	USD
CY2019	us-gaap	Depreciation Depreciation	972000	USD
CY2018	us-gaap	Depreciation Depreciation	1155000	USD
CY2020	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1228000	USD
CY2019	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1159000	USD
CY2018	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	0	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2666000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2520000	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2515000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	24756000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	21998000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	19082000	USD
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2018	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-763000	USD
CY2020	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-5300000	USD
CY2019	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2018	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	419000	USD
CY2019	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	480000	USD
CY2018	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	376000	USD
CY2020	egrx	Fair Value Adjustment On Accelerated Share Repurchases FairValueAdjustmentOnAcceleratedShareRepurchases	2962000	USD
CY2019	egrx	Fair Value Adjustment On Accelerated Share Repurchases FairValueAdjustmentOnAcceleratedShareRepurchases	0	USD
CY2018	egrx	Fair Value Adjustment On Accelerated Share Repurchases FairValueAdjustmentOnAcceleratedShareRepurchases	0	USD
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2019	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2018	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2704000	USD
CY2020	us-gaap	Restructuring Costs RestructuringCosts	0	USD
CY2019	us-gaap	Restructuring Costs RestructuringCosts	0	USD
CY2018	us-gaap	Restructuring Costs RestructuringCosts	5769000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3113000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-18481000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	12665000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1509000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1739000	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5556000	USD
CY2020	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	-11386000	USD
CY2019	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	4841000	USD
CY2018	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	570000	USD
CY2018	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	-4838000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	2325000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	599000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	806000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4455000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2064000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-4429000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	4067000	USD
CY2018	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	8128000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	49497000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	55986000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	52384000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	747000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	777000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	133000	USD
CY2019	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2018	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	17500000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-18247000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-777000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-133000	USD
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	34999000	USD
CY2019	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	17961000	USD
CY2018	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	73105000	USD
CY2020	egrx	Paymentsfor Contingent Consideration PaymentsforContingentConsideration	0	USD
CY2019	egrx	Paymentsfor Contingent Consideration PaymentsforContingentConsideration	0	USD
CY2018	egrx	Paymentsfor Contingent Consideration PaymentsforContingentConsideration	15000000	USD
CY2020	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	110000000	USD
CY2019	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	USD
CY2020	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	110000000	USD
CY2019	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	326000	USD
CY2018	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1525000	USD
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	198000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	8615000	USD
CY2019	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
CY2018	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	5000000	USD
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	6000000	USD
CY2018	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	3750000	USD
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-37870000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-24225000	USD
CY2018	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2020	egrx	Payments For Employee Options Exercised PaymentsForEmployeeOptionsExercised	0	USD
CY2019	egrx	Payments For Employee Options Exercised PaymentsForEmployeeOptionsExercised	0	USD
CY2018	egrx	Payments For Employee Options Exercised PaymentsForEmployeeOptionsExercised	4877000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3654000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	260000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6620000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-88117000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	30984000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-35866000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	109775000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78791000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	114657000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	103155000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	109775000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78791000	USD
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	6428000	USD
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	6673000	USD
CY2018	us-gaap	Income Taxes Paid IncomeTaxesPaid	2281000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	2224000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	2478000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	2084000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	855000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3716000	USD
CY2020Q4	egrx	Number Of Products NumberOfProducts	3	product
CY2020	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2020	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	3682176	shares
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	206900000	USD
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These financial statements are presented in U.S. dollars and are prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements including disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. The Company’s critical accounting policies are those that are both most important to the Company’s financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. The Company anticipates that the COVID-19 pandemic will continue to disrupt the Company’s supply chain and marketing and sales efforts for certain of its products, including Bendeka, although it is not currently expected that any disruption would be significant. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates, and any such differences may be material to the Company’s financial statements. </span></div>Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which generally is at the time we ship the product to the customer. Provisions for rebates, discounts, and returns are established in the same period the related sales are recognized. Significant judgments must be made in determining the transaction price for our sales of products related to anticipated rebates, discounts and returns. Refer below for further details.
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	79682000	USD
CY2020Q4	us-gaap	Other Assets Fair Value Disclosure OtherAssetsFairValueDisclosure	12200000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	91882000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	85625000	USD
CY2019Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	85625000	USD
CY2020	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	2700000	USD
CY2019	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	2400000	USD
CY2018	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	3300000	USD
CY2018Q4	egrx	Sales Revenue Allowance SalesRevenueAllowance	12459000	USD
CY2019	egrx	Sales Revenue Allowance Provisions And Adjustments SalesRevenueAllowanceProvisionsAndAdjustments	23822000	USD
CY2019	egrx	Sales Revenue Allowance Credits And Payments SalesRevenueAllowanceCreditsAndPayments	27181000	USD
CY2019Q4	egrx	Sales Revenue Allowance SalesRevenueAllowance	9100000	USD
CY2020	egrx	Sales Revenue Allowance Provisions And Adjustments SalesRevenueAllowanceProvisionsAndAdjustments	30230000	USD
CY2020	egrx	Sales Revenue Allowance Credits And Payments SalesRevenueAllowanceCreditsAndPayments	27528000	USD
CY2020Q4	egrx	Sales Revenue Allowance SalesRevenueAllowance	11802000	USD
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2974678	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2454077	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1824728	shares
CY2020	us-gaap	Net Income Loss NetIncomeLoss	11989000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	14313000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	31903000	USD
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13481525	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13754516	shares
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14768625	shares
CY2020	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	289868	shares
CY2019	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	384217	shares
CY2018	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	510026	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13771393	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14138733	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15278651	shares
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.89
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.04
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.16
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.87
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.01
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.09
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	3515000	USD
CY2019Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2460000	USD
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	2589000	USD
CY2019Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	3243000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1971000	USD
CY2019Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	863000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	8075000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	6566000	USD
CY2019Q4	egrx	Advancestocommercialmanufactures Advancestocommercialmanufactures	2462000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7268000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6521000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5191000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4319000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2077000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2202000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	872000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	972000	USD
CY2020Q4	egrx	Advancestocommercialmanufactures Advancestocommercialmanufactures	660000	USD
CY2020Q4	egrx	Prepaid Fda User Fee And Advances To Clinical Research Organizations PrepaidFDAUserFeeAndAdvancesToClinicalResearchOrganizations	1262000	USD
CY2019Q4	egrx	Prepaid Fda User Fee And Advances To Clinical Research Organizations PrepaidFDAUserFeeAndAdvancesToClinicalResearchOrganizations	6345000	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	191000	USD
CY2019Q4	us-gaap	Prepaid Insurance PrepaidInsurance	191000	USD
CY2020Q4	us-gaap	Prepaid Taxes PrepaidTaxes	0	USD
CY2019Q4	us-gaap	Prepaid Taxes PrepaidTaxes	4661000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1605000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1445000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3718000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15104000	USD
CY2020Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	5996000	USD
CY2019Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	6004000	USD
CY2020Q4	egrx	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	2724000	USD
CY2019Q4	egrx	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	1686000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2370000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1926000	USD
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	4686000	USD
CY2019Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	8083000	USD
CY2020Q4	egrx	Accrued Product Sales Reserves Current AccruedProductSalesReservesCurrent	4966000	USD
CY2019Q4	egrx	Accrued Product Sales Reserves Current AccruedProductSalesReservesCurrent	8364000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3075000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2298000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23817000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	28361000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	1323000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	1146000	USD
CY2020	us-gaap	Lease Cost LeaseCost	1323000	USD
CY2019	us-gaap	Lease Cost LeaseCost	1146000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	1323000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	952000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	855000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3716000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y1M6D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.060
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.060
CY2020Q4	egrx	Number Of Operating Leases NumberOfOperatingLeases	2	lease
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1391000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1423000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1455000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1038000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	413000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5720000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	638000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5082000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1123000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3959000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5082000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	8000000	USD
CY2020Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	900000	USD
CY2019Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	8000000	USD
CY2019Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	26000000	USD
CY2019Q4	us-gaap	Long Term Debt LongTermDebt	34000000	USD
CY2020	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	774489	shares
CY2019	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	317429	shares
CY2018	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	1348563	shares
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	34999000	USD
CY2019	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	17961000	USD
CY2018	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	73105000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1934193	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2556365	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	62.78
CY2018Q4	egrx	Sharebased Compensation Arrangementby Sharebased Payment Award Options Outstanding Nonexercisable Number SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingNonexercisableNumber	1074456	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1481909	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	628133	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	44.28
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	23032	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	10.33
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	65305	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3096161	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	59.29
CY2019Q4	egrx	Sharebased Compensation Arrangementby Sharebased Payment Award Options Outstanding Nonexercisable Number SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingNonexercisableNumber	1070054	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	2026107	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	762200	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	55.76
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	149473	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	24.43
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	376998	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	66.71
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3331890	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	59.20
CY2020Q4	egrx	Sharebased Compensation Arrangementby Sharebased Payment Award Options Outstanding Nonexercisable Number SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingNonexercisableNumber	1028142	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	2303748	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	28.98
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	22.18
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	26.73
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	19447000	USD
CY2020	egrx	Sharebased Compensation Arrangementby Sharebased Payment Award Options Exercised Intrinsic Value SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedIntrinsicValue	3383000	USD
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y1M6D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y9M18D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M18D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	11600000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	31900000	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	10700000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24756000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21998000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19082000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24756000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21998000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19082000	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	10140000	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	6689000	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	4137000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2059000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	844000	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	466000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	12199000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	7533000	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	4603000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1227000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	392000	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-2565000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-284000	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-240000	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	97000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1511000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	152000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2468000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10688000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7685000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2135000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.06
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.02
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.01
CY2020	egrx	Effective Income Tax Rate Reconciliation Sharebased Compensation Excess Tax Benefit EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefit	-0.04
CY2019	egrx	Effective Income Tax Rate Reconciliation Sharebased Compensation Excess Tax Benefit EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefit	-0.01
CY2018	egrx	Effective Income Tax Rate Reconciliation Sharebased Compensation Excess Tax Benefit EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefit	0.11
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.02
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.02
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.07
CY2020	egrx	Effective Income Tax Rate Reconciliation Limitation On Executive Compensation Percent EffectiveIncomeTaxRateReconciliationLimitationOnExecutiveCompensationPercent	0.09
CY2019	egrx	Effective Income Tax Rate Reconciliation Limitation On Executive Compensation Percent EffectiveIncomeTaxRateReconciliationLimitationOnExecutiveCompensationPercent	0.10
CY2018	egrx	Effective Income Tax Rate Reconciliation Limitation On Executive Compensation Percent EffectiveIncomeTaxRateReconciliationLimitationOnExecutiveCompensationPercent	0.03
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.09
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.04
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.01
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.01
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.47
CY2019Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	838000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	USD
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.35
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.06
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	841000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	243000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	12015000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	10647000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	1771000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	2338000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	1539000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	51000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	51000	USD
CY2020Q4	egrx	Deferred Tax Assets In Process Researchand Development Credit DeferredTaxAssetsInProcessResearchandDevelopmentCredit	479000	USD
CY2019Q4	egrx	Deferred Tax Assets In Process Researchand Development Credit DeferredTaxAssetsInProcessResearchandDevelopmentCredit	620000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	708000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	662000	USD
CY2020Q4	egrx	Deferred Tax Assets Operating Lease Right Of Use Asset DeferredTaxAssetsOperatingLeaseRightOfUseAsset	1154000	USD
CY2019Q4	egrx	Deferred Tax Assets Operating Lease Right Of Use Asset DeferredTaxAssetsOperatingLeaseRightOfUseAsset	925000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	86000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	737000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1017000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	20180000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	15704000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	483000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	0	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	43000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	43000	USD
CY2020Q4	egrx	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	315000	USD
CY2019Q4	egrx	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	203000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1092000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1933000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1084000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3067000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	951000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	15180000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	13669000	USD
CY2017Q3	egrx	Clinical Development Cost Sharing Percentage ClinicalDevelopmentCostSharingPercentage	0.50
CY2020	egrx	Product Development Agreements Exclusive Rights Acquired Numberof Products ProductDevelopmentAgreementsExclusiveRightsAcquiredNumberofProducts	33	product
CY2020	egrx	Marketing Rights Term MarketingRightsTerm	P10Y
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5720000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1391000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1423000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1455000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1038000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	413000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	34000000	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	8000000	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	26000000	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	0	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	0	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	0	USD
CY2020Q4	us-gaap	Purchase Obligation PurchaseObligation	68644000	USD
CY2020Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	68644000	USD
CY2020Q4	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	0	USD
CY2020Q4	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	0	USD
CY2020Q4	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	0	USD
CY2020Q4	us-gaap	Purchase Obligation Due In Fifth Year PurchaseObligationDueInFifthYear	0	USD
CY2020Q4	egrx	Obligations Future Payments ObligationsFuturePayments	108364000	USD
CY2020Q4	egrx	Obligations Future Payments Due Remainder Of Fiscal Year ObligationsFuturePaymentsDueRemainderOfFiscalYear	78035000	USD
CY2020Q4	egrx	Obligations Future Payments Due In Second Year ObligationsFuturePaymentsDueInSecondYear	27423000	USD
CY2020Q4	egrx	Obligations Future Payments Due In Third Year ObligationsFuturePaymentsDueInThirdYear	1455000	USD
CY2020Q4	egrx	Obligations Future Payments Due In Fourth Year ObligationsFuturePaymentsDueInFourthYear	1038000	USD
CY2020Q4	egrx	Obligations Future Payments Due In Fifth Year ObligationsFuturePaymentsDueInFifthYear	413000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	1323000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	1146000	USD
CY2018	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	571000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5720000	USD
CY2020Q4	us-gaap	Purchase Obligation PurchaseObligation	68644000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	23100000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	10183000	USD
CY2020Q4	egrx	Finite Lived Intangible Assets Impairment FiniteLivedIntangibleAssetsImpairment	0	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	12917000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	23100000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7517000	USD
CY2019Q4	egrx	Finite Lived Intangible Assets Impairment FiniteLivedIntangibleAssetsImpairment	0	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	15583000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2700000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2500000	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2500000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2622000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1369000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1570000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1898000	USD
CY2020Q4	egrx	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	5458000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	12917000	USD
CY2018	us-gaap	Restructuring Charges RestructuringCharges	7911000	USD

Files In Submission

Name	View Source	Status
0000827871-21-000011-index-headers.html	Edgar Link	pending
0000827871-21-000011-index.html	Edgar Link	pending
0000827871-21-000011.txt	Edgar Link	pending
0000827871-21-000011-xbrl.zip	Edgar Link	pending
egrx-20201231.htm	Edgar Link	pending
egrx-20201231.xsd	Edgar Link	pending
egrx-20201231_cal.xml	Edgar Link	unprocessable
egrx-20201231_def.xml	Edgar Link	unprocessable
egrx-20201231_g1.jpg	Edgar Link	pending
egrx-20201231_htm.xml	Edgar Link	completed
egrx-20201231_lab.xml	Edgar Link	unprocessable
egrx-20201231_pre.xml	Edgar Link	unprocessable
exhibit1029formofpsutsr.htm	Edgar Link	pending
exhibit1030formofpsumilest.htm	Edgar Link	pending
exhibit21110k2020.htm	Edgar Link	pending
exhibit23110k2020.htm	Edgar Link	pending
exhibit232bdoconsent.htm	Edgar Link	pending
exhibit31110k2020.htm	Edgar Link	pending
exhibit31210k2020.htm	Edgar Link	pending
exhibit32110k2020.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx

2020 Q4 Form 10-K Financial Statement

#000082787121000011 Filed on March 05, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EGRX EAGLE PHARMACEUTICALS, INC. Stock $egrx

2020 Q4 Form 10-K Financial Statement

#000082787121000011 Filed on March 05, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx